Immunohistochemical studies of transforming growth factor-β and its receptors in the gastric mucosa of patients with refractory gastric ulcer

Journal of the Formosan Medical Association

Volumn 98, Issue 9, 1999, Pages 613-620

  Shih, Shou Chuan ^a   Chien, Chung Liang ^b   Tseng, Kwang Wen ^b   Lin, Shee Chan ^a   Kao, Chin Roa ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Gastric ulcer healing; Immunohistochemistry; Refractory gastric ulcer; Transforming growth factor beta; Transforming growth factor beta receptor

Indexed keywords

CIMETIDINE; RANITIDINE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL ARTICLE; FEMALE; HELICOBACTER PYLORI; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; STOMACH MUCOSA; STOMACH ULCER; TISSUE REPAIR; ULCER HEALING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTRIC MUCOSA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; STOMACH ULCER; TRANSFORMING GROWTH FACTOR BETA; TREATMENT FAILURE;

EID: 0032730673     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. 2-receptor antagonists. Aliment Pharmacol Ther 1996;10:387-96.
2. 2-receptor antagonists. Abdom Imaging 1996;21:133-41.
3. Nakajima T: Studies on factors affecting healing of gastric ulcer. A prospective, cooperative study in Japan. Am J Gastroenterol 1976;66:150-4.
4. Li H, Kalies I, Mellgard B, et al: A rat model of chronic Helicobacter pylori infection. Studies of epithelial cell turnover and gastric ulcer healing. Scand J Gastroenterol 1998; 33:370-8.
5. Bui HX, del Rosario A, Sonbati H, et al: Helicobacter pylori affects the quality of experimental gastric ulcer healing in a new animal model. Exp Mol Pathol 1991;55: 261-8.
6. Schmassmann A: Mechanisms of ulcer healing and effects of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104:3S-51S;79S-80S.
7. Ogihara Y, Okabe S: Mechanism by which indomethacin delays gastric ulcer healing in the rat: inhibited contraction of the ulcer base. Jpn J Pharmacol 1993;61: 123-31.
8. McCarthy DM: Smoking and ulcers - time to quit. N Engl J Med 1984;311:726-8.
9. van Rensburg CJ, Louw JA, Girdwood AH, et al: A trial of lansoprazole in refractory gastric ulcer. Aliment Pharmacol Ther 1996;10:381-6.
10. 2-receptor antagonist-refractory ulcer: its pathophysiology and treatment. J Clin Gastroenterol 1991;13 (Suppl 1):129-33.
11. Walan A, Bader JP, Classen M, et al: Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer N Engl J Med 1989; 320: 69-75.
12. 2 on human gastric ulcers. Gastroenterol Jpn 1982;17:21-4.
13. Tominaga K, Arakawa T, Kim S, et al: Increased expression of transforming growth factor-beta1 during gastric ulcer healing in rats. Dig Dis Sci 1997;42:616-25.
14. Guglietta A, Hervada T, Nardi RV, et al: Effect of platelet derived growth factor-BB on indomethacin-induced gastric lesions in rats. Scand J Gastroenterol 1992;27:673-6.
15. Konturek PC, Brzozowski T, Konturek SJ, et al: Expression of epidermal growth factor and transforming growth factor alpha during ulcer healing. Time sequence study. Scand J Gastroenterol 1997;32:6-15.
16. Coerper S, Sigloch E, Cox D, et al: Recombinant human transforming growth factor beta 3 accelerates gastric ulcer healing in rats. Scand J Gastroenterol 1997;32:985-90.
17. Massague J, Attisano L, Wrana JL: The TGF-β family and its composite receptors. Trends Cell Biol 1994;4:172-8.
18. Wahl SM: Transforming growth factor β (TGF-β) in inflammation: a cause and a cure. J Clin Immunol 1992;12: 61-74.
19. Roberts AB, Sporn MB: Physiological actions and clinical applications of transforming growth factor β (TGF-β). Growth Factors 1993;8:1-9.
20. Lin HY, Lodish HF: Receptors for the TGF-β superfamily: multiple polypeptides and serine/threonine kinases. Trends Cell Biol 1993;3:14-9.
21. Ebner R, Chen RH, Shum L, et al: Determination of type I receptor specificity by the type II receptors for TGF-β or activin. Science 1993;262:900-2.
22. Lin HY, Moustakas A, Knaus P, et al: The soluble exoplasmic domain of the type II transforming growth factor (TGF)-β receptor: a heterogeneously glycosylated protein with high affinity and selectivity for TGF-β ligands. J Biol Chem 1995;270:2747-54.
23. Gold LI, Sung JJ, Siebert JW, et al: Type I (RI) and type II (RII) receptors for transforming growth factor (TGF)-β isoforms are expressed subsequent to transforming growth factor β ligands during excisional wound repair. Am J Pathol 1997;150:209-22.
24. Lam SK, Lai CL: Gastric ulcers with and without associated duodenal ulcer have different pathophysiology. Clin Sci Mol Med 1978;55:97-102.
25. Maton PN: Omeprazole. N Engl J Med 1991;324: 965-75.
26. Lazzaroni M, Perego M, Bargiggia S, et al: Helicobacter pylori eradication in the healing and recurrence of benign gastric ulcer: a two-year, double-blind, placebo controlled study. Ital J Gastroenterol Hepatol 1997;29: 220-7.
27. Corboy ED Jr, Clay GA, Fakouhi DT, et al: Humanitarian use of misoprostol in severe refractory upper gastrointestinal disease. Am J Med 1987;83:49-52.
28. Konturek PC, Brzozowski T, Konturek SJ, et al: Epidermal growth factor and transforming growth factor a: role in protection and mucosal lesions. Eur J Gastroenterol 1995;7:933-8.
29. Abe S, Sasano H, Katoh K, et al: Immunohistochemical studies on EGF family growth factors in normal and ulcerated human gastric mucosa. Dig Dis Sci 1997;42: 1199-209.